Ipertrofan (Mepartricin)

Mepartricin exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria. This binding blocks the translocation step of protein synthesis, preventing the formation of essential proteins and resulting in a bacteriostatic effect that limits bacterial growth.

The dosage of Ipertrofan is individualized by the treating physician based on the type and severity of the infection, patient weight, renal and hepatic function, and local antimicrobial guidelines. Patients should follow the prescriber’s instructions and the label directions precisely.

Safety data for mepartricin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient before prescribing.

To request Ipertrofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipertrofan (mepartricin) shares the macrolide class’s mechanism of inhibiting bacterial protein synthesis, similar to erythromycin or azithromycin. Compared with some macrolides, mepartricin may have a different spectrum of activity, particularly against certain uropathogens, and may present a distinct side‑effect profile. Choice of therapy depends on susceptibility patterns and clinical judgment.

Ipertrofan tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ipertrofan is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless directed by a healthcare professional. Administration can be with or without food, but consistency with meals may help reduce gastrointestinal discomfort.

The most serious adverse events include severe allergic reactions such as anaphylaxis, hepatotoxicity manifested by elevated liver enzymes or jaundice, Clostridioides difficile‑associated colitis, and cardiac arrhythmias like QT prolongation. Patients should seek immediate medical attention if they experience symptoms such as rash, difficulty breathing, persistent diarrhea, or palpitations.

Ipertrofan is contraindicated in individuals with a known hypersensitivity to mepartricin or any macrolide antibiotic. It should also be avoided in patients with a history of severe liver disease, those taking medications that may cause dangerous interactions (e.g., certain statins, cyclosporine, warfarin) unless closely monitored, and in pregnant or breastfeeding women unless the benefit justifies the risk.